On Tuesday, ACADIA Pharmaceuticals Inc ACAD will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
Earnings and Revenue
ACADIA's per-share loss will be near 57 cents per share on sales of $44.3 million, according to Wall Street analysts.
ACADIA reported a per-share loss of 65 cents when it published results during the same quarter last year. Sales in that period totaled $11.9 million. If the company were to report inline earnings when it publishes results Tuesday, earnings would be down 10.77 percent. Sales would be up 270.51 percent from the year-ago period.
ACADIA's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
| EPS Estimate | -0.62 | -0.72 | -0.73 | -0.65 |
| EPS Actual | -0.53 | -0.55 | -0.72 | -0.65 |
Stock Performance
Over the past 52-week period, shares of ACADIA have declined 20.32 percent.
Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. Analysts seem to have settled on a Neutral rating with ACADIA Pharmaceuticals. The strength of this rating has maintained conviction over the past three months.
Conference Call
ACADIA is scheduled to hold a conference call at 4:00 p.m. ET and it can be accessed here:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
